NTRK3 and cancer: We observed similar results with respect to NTRK3, as NTRK3 mutation was also associated with improved overall survival in the combined cohort (Fig. 7D), and was most frequent in melanoma patients, followed by cancers of unknown primary and NSCLC (Fig. 7E).